Clinical-stage biopharmaceutical company Windtree Therapeutics, Inc. has emerged as a key player in the field of cardiovascular disease medicine. The company is focused on developing new therapeutics for acute conditions in this area, with lead programs centered around istaroxime and aerosolized KL4 surfactant. These programs are currently undergoing Phase 2b clinical trials for the treatment of decompensated heart failure and respiratory distress syndrome in premature infants, respectively. Windtree's other Phase 2a programs include Surfaxin for COVID-19-induced lung injury and rostafuroxin for genetically associated hypertension, as well as an oral and intravenous SERCA2a activator in preclinical trial for heart failure. Windtree Therapeutics also has prominent collaborations with Universita degli Studi di Milano-Bicocca, Laboratorios del Dr. Esteve, S.A. and Battelle Memorial Institute. The former two are focused on the development of new SERCA2a compounds and KL4 surfactant products, while the latter is focused on developing the company's ADS for use in Phase III trials. Windtree Therapeutics was founded in 1992 and is headquartered in Warrington, Pennsylvania, having changed its name from Discovery Laboratories, Inc. in April 2016.